SRR35579826
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.420
- HEDGEHOG_SIGNALING+0.310
- OXIDATIVE_PHOSPHORYLATION+0.280
- ANGIOGENESIS+0.250
- ESTROGEN_RESPONSE_EARLY+0.200
- ADIPOGENESIS+0.170
- MYOGENESIS+0.160
- ESTROGEN_RESPONSE_LATE+0.150
- BILE_ACID_METABOLISM+0.130
- HEME_METABOLISM+0.110
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.570
- ALLOGRAFT_REJECTION-0.440
- IL6_JAK_STAT3_SIGNALING-0.440
- INFLAMMATORY_RESPONSE-0.410
- CHOLESTEROL_HOMEOSTASIS-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- HYPOXIA-0.300
- MTORC1_SIGNALING-0.290
- COMPLEMENT-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A093-01A-11R-A00Z-07 | — | B | 0.816 |
| 2 | MBCProject_0297_T1_RNA | — | A | 0.791 |
| 3 | SRR35579847 | — | B | 0.785 |
| 4 | AUR-AD9E-TTM2-A-1-1-R-A542-39 | — | B | 0.771 |
| 5 | SRR25617874 | — | B | 0.767 |
| 6 | 643bb711-7302-4ba7-bd39-cb0e4d9c2377 | — | — | 0.762 |
| 7 | 0177d00d-7d3f-43c8-8d0f-e6333e73efa4 | — | — | 0.758 |
| 8 | TCGA-A7-A0D9-01A-31R-A056-07 | — | B | 0.751 |
| 9 | SRR8518374 | — | E | 0.749 |
| 10 | SRR25617843 | — | B | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| COAGULATION | 0.020 | Binimetinib | — uncovered |